P4‐157: Citalopram and Rivastigmine Treatment for Alzheimer’s Disease | Zendy

Pathak Krishna Prasad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

P4‐157: Citalopram and Rivastigmine Treatment for Alzheimer’s Disease

Author(s) -

Pathak Krishna Prasad

Publication year - 2016

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2016.06.2249

Subject(s) - rivastigmine , citalopram , depression (economics) , medicine , dementia , rating scale , geriatric depression scale , clinical dementia rating , psychology , anesthesia , disease , psychiatry , donepezil , antidepressant , cognition , depressive symptoms , developmental psychology , macroeconomics , hippocampus , economics

no difference between groups in prior COPD diagnoses (11.1% vs. 9.1%, p1⁄4.71) and a trend towards a lower smoking history (25.0% vs. 42.8%, p1⁄4.05). Controlling for age and gender, abnormal FEV1/FVC ratios increased risk of poor cognitive performance (OR1⁄48.78; 2.4-31.8). Hippocampal volumes (R1⁄4.296, p1⁄4.03) and precuneus glucose metabolism (R1⁄4.286, p1⁄4.04) correlated with FEV1/FVC ratios. For every 0.5 difference between Lung Age/Chronological Age ratio, the MoCA reduced by 1 point (B1⁄4-0.55;T1⁄4-3.13,p1⁄4.002). Conclusions: The presence of COPD is associated with poorer cognitive performance and correlated with AD-related biomarkers (smaller hippocampal volumes, decreased precuneus glucose metabolism). Incorporating spirometry in the evaluation of older adults may help identify individuals at-risk for cognitive impairment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research